This study analyzed characteristics, survival rates, and prognostic factors in 133 patients with bone metastases from differentiated thyroid carcinoma over a follow-up period of 40 months.
It found that the survival rates were 53.5% at 3 years, 39.5% at 5 years, and 28.5% at 10 years, with significant factors affecting survival including age, lymph node metastases, and treatment with I131.
The research highlighted that patients treated with I131 had better outcomes, while older age and lymph node involvement were linked to increased mortality.